Dysplasia at the surgical margin is associated with recurrence after resection of non‐invasive intraductal papillary mucinous neoplasms  by Frankel, Timothy L. et al.
ORIGINAL ARTICLE
Dysplasia at the surgical margin is associated with recurrence after
resection of non-invasive intraductal papillary mucinous neoplasms
Timothy L. Frankel, Jennifer LaFemina, Zubin M. Bamboat, Michael I. D'Angelica, Ronald P. DeMatteo, Yuman Fong,
T. Peter Kingham, William R. Jarnagin & Peter J. Allen
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Abstract
Background: The significance of a positive margin in resected non-invasive pancreatic intraductal
papillary mucinous neoplasms (IPMN) remains controversial. The aim of this study was to determine
recurrence rates when dysplasia was present at the final surgical margin.
Methods: A prospectively maintained database identified 192 patients undergoing resection of non-
invasive IPMN. Pathological, peri-operative and recurrence data were analysed.
Results: Ductal dysplasia was identified at the final surgical margin in 86 patients (45%) and defined
as IPMN or Pancreatic Intraepithelial Neoplasia PanIN in 38 (20%) and 54 (28%) patients, respectively.
At a median follow-up of 46 months, 40 (21%) patients recurred with 31 developing radiographical
evidence of new cysts, 6 re-resected for IPMN and 3 diagnosed with pancreatic cancer within the
remnant. Of those with margin dysplasia, 31% developed recurrent disease compared with 13% in
those without dysplasia (P = 0.002). On multivariate analysis, margin dysplasia was associated with a
three-fold increased risk of recurrence (P = 0.02). No relationship between dysplasia and development
of pancreatic cancer was found.
Discussion: In this study, dysplasia at the margin after a pancreatectomy for non-invasive IPMN was
associated with recurrence in the remnant gland, but not at the resection margin. While this finding may
warrant closer follow-up, it does not identify a gland at higher risk for the subsequent development of
invasive disease.
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Introduction
Intraductal papillary mucinous neoplasms (IPMN) are defined
as cystic lesions of the pancreas lined with mucin-producing epi-
thelium with characteristic papillary proliferation.1–3 Typically
classified as a branch duct or main duct type based on the distri-
bution of pancreatic ductal involvement, IPMN are believed to
represent a spectrum of pre-malignant to malignant lesions
ranging from adenoma to carcinoma in situ and occasionally
invasive adenocarcinoma.4,5 The treatment of IPMN remains con-
troversial with most agreeing that small branch duct lesions can
be followed with cross-sectional imaging whereas larger cysts
or those with mural nodules or other solid components should
be resected.6,7 Once the decision to operate has been made,
approaches include parenchymal-preserving operations such as
enucleation or a central pancreatectomy,8–10 pancreaticoduo-
denectomy, distal pancreatectomy, or in the case of diffuse
disease, a total pancreatectomy.11,12
After a resection, pathological review of the surgical specimen
focuses on identification of invasive carcinoma and assessment of
the degree of dysplasia of the cyst lining and surgical margin. The
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latter has created considerable controversy regarding its oncologi-
cal significance and the need for further resection in non-invasive
IPMN.13,14 While some believe a positive margin represents
residual pre-neoplastic tissue capable of malignant transforma-
tion, others suggest it is simply a marker of diffuse dysplasia
throughout the gland with little oncological importance. Initial
guidelines on the management of pancreatic cysts recommended
frozen section evaluation of the margin during IPMN resections
with re-excision for all but benign or adenomatous findings.7 The
theoretical goal of a re-resection was to eliminate the potential risk
of malignant transformation of dysplastic residual epithelium. A
re-resection, however, is associated with increased morbidity and
often results in continuedmargin positivity occasionally requiring
a total pancreatectomy if a negative margin is to be achieved.14
Recent studies have questioned the significance of positive
margins in non-invasive IPMN with regard to recurrence of both
IPMN and pancreas cancer in the remnant gland.14–16 In a previ-
ous study from our institution of 78 patients who underwent
resection of non-invasive IPMN, the risk of local recurrence after
a median follow-up of 40 months was 8%.17 An association
between margin status and recurrence was identified and recur-
rence was defined as radiographical appearance of pancreas
cancer or an IPMN that required operative intervention.
In the present study, we evaluated clinical and pathological
characteristics of 192 patients who underwent a resection for non-
invasive IPMN. Recurrence included patients who developed
radiographical evidence of new IPMN regardless of re-resection.
Using these factors we identified predictors of both margin posi-
tivity and recurrent disease after a resection.
Methods
Patients
An institutional review board-approved prospectively maintained
database of patients undergoing a pancreatic resection at Memo-
rial Sloan-Kettering Cancer Center (MSKCC) was used to identify
192 patients who underwent a resection of non-invasive IPMN.
Patients with invasive cancer and those undergoing a total pan-
createctomy were excluded from analysis. All patients had disease
confirmed by both radiographical and pathological analysis.
Patient demographics, details on presentation as well as radio-
graphical and follow-up data were collected and reviewed. Typi-
cally, a resection was recommended in the setting of main duct
disease and branch duct cysts which were symptomatic, >2.5 cm
in size, displaying evidence of growth, or when worrisome features
such as mural nodules were present. After a resection, patients
were followed with serial cross-sectional imaging assessing for
evidence of new cystic or solid lesions.
Pathology
All surgical specimens were reviewed by gastrointestinal patholo-
gists with extensive experience in pancreatic diseases. Cyst size was
recorded based on the gross pathological measurement. Lesions
were classified in accordance with World Health Organization
(WHO) consensus guidelines as low-grade, moderate-grade or
high-grade dysplasia.When possible, the epitheliumwas subtyped
as gastric, intestinal, pancreatobiliary or oncocytic. Both imaging
and pathological analyses were used to characterize the extent of
involvement as a branch duct, main duct or mixed type. The
uninvolved gland was assessed for the presence of fibrosis, pan-
creatitis and/or extra-cystic pancreatic intraepithelial neoplasia
(PanIN). In addition to the primary lesion, a section of ductal
epithelium at the transection margin was evaluated for the pres-
ence and grade of IPMN or PanIN. A positive margin was defined
as IPMN or PanIN present at the final surgical margin regardless
of degree of dysplasia. In selected patients, an intra-operative
frozen section was performed and the results collected and com-
pared with the final reported margin. When additional margins
were taken, data regarding residual disease were recorded.
Statistical analysis
Nominal variables were evaluated using two-tailed c2 or Fisher’s
exact tests when appropriate. Continuous variables were assessed
with univariate logistic regression for parametric values and Wil-
coxon’s rank sum for non-parametric values. Multivariate logistic
regression models were created using all factors with an alpha
<0.10 on univariate analysis and variables previously identified as
associated margin positivity or recurrence. Kaplan–Meier survival
curves were created to determine differences in survival and
P-values <0.05 were considered significant.
Results
Demographics
Between 1990 and 2010, 268 patients underwent a pancreatic
resection for IPMN at MSKCC. Invasive cancer was identified on
final pathology in 72 patients and these patients were excluded
from further analysis. In 192 patients with non-invasive IPMN,
the mean age at operation was 68 years with slightly more female
patients (55%). Lesions were most often discovered incidentally
during cross-sectional imaging or ultrasonography obtained for
other purposes (54%). Symptoms were present in 88 patients
(46%) at the time of presentation with the most commonly
reported symptoms being pain (35%) and weight loss (11%).
Every patient had pre-operative cross-sectional imaging with
either a computed tomography scan or magnetic resonance
imaging prior to intervention to assess size and extent of the
disease as well as any worrisome features such as cyst wall thick-
ening or mural nodules. Imaging revealed a dilated main pancre-
atic duct (>4 mm) in 55% of patients and nodularity of the cyst
wall in 7%. Endoscopic ultrasound was performed in 38 patients
(20%) with fluid aspiration and analysis revealing a mean cyst
fluid carcinoembryonic antigen level of 1760 ng/ml (range
79–38530).
The most common indications for operative intervention were
size at presentation (51%), enlargement of cysts on serial imaging
(22%), biopsy suspicious for cancer or high grade dysplasia (16%)
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and radiographical evidence of a mass or nodule (7%).
Operations included 125 pancreaticoduodenectomies, 53 distal
pancreatectomies and 14 parenchymal-preserving procedures
(enucleation or central pancreatectomy). After resection of the
index lesion, 10 patients with multifocal IPMN were left with
residual cysts which did not meet resection criteria.
Histopathology and margin status
On pathological evaluation, 23% of lesions were classified as
low-grade, 46% moderate-grade and 31% high-grade lesions
(Table 1). Gastric type epithelium was most common (62%),
whereas intestinal, pancreatobiliary and oncocytic type was iden-
tified in 29%, 9% and 2%, respectively.Most lesions were classified
as branch duct type (49%) and the rest main duct (25%) and
mixed type (26%). The mean cyst size on gross examination was
2.7 cm. The unaffected gland was assessed for pathological abnor-
malities with evidence of pancreatitis discovered in 47% and
fibrosis in 14%. PanIN was discovered in the extra-cystic pancre-
atic duct exclusive of the margin in 39% of specimens and ranged
in degree from PanIN 1 (15%) to PanIN 2 (20%) and PanIN 3
(4%).
The pancreatic ductal margin was assessed in each patient and
the results are summarized in Table 2. IPMN or PanIN was dis-
covered at the final surgical margin in 38 (20%) and 54 (28%)
specimens, respectively. Six patients had both IPMN and PanIN
identified. An intra-operative frozen section was performed in 44
cases (23%) and revealed residual disease in 17 patients (39% of
frozen sections). This disease was most often low-grade IPMN
(71% of positive frozen sections) with moderate- and high-grade
IPMN found in 18% and 11% of patients, respectively. Of the 44
cases in which a frozen section was utilized, a re-resection was
performed in 4 cases (9%) with 2 resulting in a negative final
margin. When comparing frozen section results with those found
on final pathology, there was concordance in 57% of cases result-
ing in a positive predictive value of 41.2% and a negative predic-
tive value of 66.7%.
At a median follow-up of 46 months, 40 patients (21%) had
recurrent disease (Table 3) defined as appearance of new cysts
suspicious for IPMN on imaging (31 patients), pathological con-
firmation of IPMN on re-resection (6 patients) or the develop-
ment of pancreatic cancer (3 patients). Patients with residual cysts
after their index operation were not counted as recurrences unless
they required a repeat operation (n = 1). Of the three patients who
developed pancreas cancer, the original lesions displayed low- and
high-grade dysplasia in 1 and 2 patients, respectively. Examination
of the margins in the patients who developed cancer revealed
high-grade dysplasia in one patient whereas the other 2 patients
had negative margins. The discovery of cancer was at 10, 39 and 67
months after the resection and none developed cancer at the
resected margin. Seven patients (4%) with presumed recurrent
IPMN underwent a second operation during the follow-up period
Table 1 Pathological features of resected non-invasive intraductal
papillary mucinous neoplasms (IPMN) in 192 patients
Path n = 192
IPMN type
Low grade (n = 44) 23%
Moderate grade (n = 88) 46%
High grade (n = 60) 31%
Subtype
Branch (n = 94) 49%
Main (n = 47) 25%
Mixed (n = 50) 26%
Epithelium
Gastric (n = 58) 62%
Intestinal (n = 27) 29%
Pancreato/biliary (n = 7) 7%
Oncocytic (n = 2) 2%
Size (mean) 2.7 cm (2.3)
Evidence of pancreatitis (n = 88) 47%
Fibrosis (n = 26) 14%
PanIN in the gland
None (n = 113) 61%
1 (n = 28) 15%
2 (n = 37) 20%
3 (n = 8) 4%
Table 2 Pathology of the final surgical margin in 192 patients who
underwent a resection for non-invasive intraductal papillary muci-
nous neoplasms (IPMN)
Margin
PanIN or IPMN at margin (n = 86) 45%
IPMN at final margin
None (n = 154) 80%
Low grade (n = 17) 9%
Moderate grade (n = 15) 8%
High grade (n = 6) 3%
PanIN at final margin
None (n = 138) 72%
1 (n = 33) 17%
2 (n = 17) 9%
3 (4) 2%
Frozen section (n = 44) 23%
Path on frozen
Negative (n = 27) 61%
Low grade IPMN (n = 12) 27%
Moderate grade IPMN (n = 3) 7%
High grade IPMN (n = 1) 2%
PanIN (n = 1) 2%
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including 3 segmental resections and 3 completion pancreatecto-
mies. One of the 6 patients had no evidence of recurrent IPMN on
final pathological analysis.
When patients recurred, this was predominantly away from the
surgical margin with only 8% havingmargin-only recurrence. The
vast majority recurred elsewhere in the remnant gland (80%) or
diffusely (8%) (Fig. 1). Of the six patients who recurred at the
margin of resection, half had no evidence of PanIN or IPMN at
the initial surgical margin.
Predictors of margin positivity
Univariate analysis of demographic and pathological data was
performed to identify predictors of a positive final surgical margin
after resection for non-invasive IPMN. The risk of a positive
margin varied significantly with the degree of IPMN dysplasia.
Patients with moderate- or high-grade dysplasia had a signifi-
cantly increased risk of having a positive margin (50%) when
compared with patients with low-grade dysplasia (22%) (P =
0.002) (Fig. 2). Other predictors of margin status included loca-
tion of the cyst, epithelial type and the presence of PanIN in the
extracystic pancreatic duct. There was a non-significant trend
towards increased cyst size in patients with positive margins (2.5
versus 3 cm in negative and positive margins, respectively; P =
0.17). There was no difference in margin status between patients
with main duct (47%) compared with branch duct IPMN (44%)
(P = 0.86).
Using multivariate regression (Table 4), the degree of dysplasia
remained significant with high-grade IPMN associated with a
10-fold increase in positive margins (P = 0.03). The presence of
extra-cystic PanIN alsomaintained significance with an odds ratio
of 5.7 (P = 0.001).
Predictors of disease recurrence
The above factors including margin status were used to identify
predictors of recurrent disease after a pancreatectomy for IPMN
(Table 5). On univariate analysis, the location of the cyst within
the tail or body was associated with a significant increased rate of
recurrence. When PanIN was present at the resection margin, the
recurrence rate was nearly double (P = 0.02). If any dysplasia
(IPMN or PanIN) was present the recurrence rate was 31% com-
pared with 12% when a negative margin was found (P = 0.002).
On multivariate analysis (Table 6), location within the body was
associated with a 4.8-fold increased risk of recurrent disease (P =
0.01). When IPMN or PanIN was present at the final surgical
margin, there was a three-fold increase (P = 0.02).
Kaplan–Meier curves were created to determine differences in
recurrence-free and overall survival based on margin status
(Fig. 3). Although patients with dysplasia at the margin had sig-
nificantly worse disease-free survival (P = 0.001), this did not
translate to a worse overall survival (P = 0.55).
Table 3 Recurrence and follow-up data on 192 patients with a
resected non-invasive intraductal papillary mucinous neoplasms
(IPMN)
Recurrence
Median follow-up 46 months
Recurrence (n = 40) 21%
Location of recurrence
Remnant gland (n = 32) 80%
Margin (n = 3) 8%
Remnant gland and margin (n = 3) 8%
Unknown (n = 2) 5%
Re-operation (n = 6) 3%
Pancreas cancer (n = 3) 2%
Figure 1 Location of recurrence of follow-up imaging. The white
arrow marks a recurrent cyst. (a) Remnant recurrence. (b) Margin
recurrence
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Discussion
With increased utilization of cross-sectional imaging, the inci-
dence of IPMN has risen dramatically over the past two dec-
ades.18,19 Lesions are often discovered when small and
asymptomatic leading to considerable controversy in their man-
agement. At the crux of the debate is the potential for IPMN to
progress to pancreatic adenocarcinoma which, when found in
later stages, is almost universally fatal. In an attempt to standardize
management, an International Consensus Guideline7 was pub-
lished which recommended resection of suspected IPMN which
were greater than 3 cm in size and/or had suspicious features such
as mural nodules, a dilated pancreatic duct or positive cytology.
An intra-operative frozen section was recommended at the time of
operation with re-resection if the margin showed evidence of
moderate- or high-grade dysplasia. Admittedly, this recommen-
dation was made with little supporting data and the clinical sig-
nificance of a positive margin remains controversial, particularly
in non-invasive IPMN.
There are two types of dysplastic epithelium found at the
transected margin of the pancreas: IPMN and PanIN.2,20When
IPMN is present, the degree of dysplasia is determined by irregu-
larity of the papilla, nuclear crowding andmitosis and is described
according to aWHO consensus statement as low- (adenomatous),
moderate- or high-grade (carcinoma in situ).4 PanIN also repre-
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Figure 2 Margin status and recurrence by degree of dysplasia
Table 4 Multivariate predictors of a positive margin
Odds ratio P-value
Pain 1.8 0.31
Weight loss 3.1 0.27
Degree of dysplasia 0.03
Adenoma Referent
Moderate 3.2
High grade 10.0
Location within the gland 0.05
Head Referent
Body 3.8
Tail 4.1
Tissue subtype 0.21
PanIN in the gland 5.7 0.001
Table 5 Univariate predictors of recurrent disease
Recurrence P-value
Gender 0.29
Male 17%
Female 24%
Race 0.56
White 18.5%
Non-white 21%
Pain at presentation 0.43
Yes 19%
No 24%
Weight loss at presentation 0.25
Yes 10%
No 24%
Dilated duct on pre-operative image 0.37
Yes 19%
No 26%
Nodule or mass on pre-operative 0.48
Yes 31%
No 21%
IPMN dysplasia 0.97
Adenoma 21%
Moderate 20%
High grade 22%
Location of cyst 0.004
Head 15%
Body 41%
Tail 27%
IPMN tissue type 0.23
Gastric 22%
Intestinal 22%
Pancreatobiliary 0%
Oncocytic 0%
IPMN distribution 0.83
Branch duct 22%
Main duct 21%
Mixed 18%
PanIN with the gland 0.10
Yes 27%
No 17%
IPMN or PanIN at margin 0.002
Yes 31%
No 12%
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sents dysplasia of the pancreatic ductal epithelium but differs
from IPMN as it lacks papilla and does not result in radiographi-
cal or pathological appearance of cysts.20 PanIN is also described
as having a spectrum of dysplasia ranging from minimal (PanIN
1) to moderate dysplasia (PanIN 2) and carcinoma in situ (PanIN
3).2 While most agree that low-grade IPMN and/or PanIN 1 at the
surgical margin can be treated as benign, many contend that
moderate- or high-grade dysplasia requires more radical resection
including in some cases a total pancreatectomy.7,21–23 Most of these
recommendations on the management of positive margins are
based on anecdotes and small case series with no convincing evi-
dence available.
In a single institution review of 19 patients undergoing segmen-
tal pancreatic resection for non-invasive IPMN, Raut et al.24
reported a 21% incidence of a positive final margin. At a median
follow-up of 34.1 months, there were no instances of recurrence in
this subset of patients leading the authors to conclude that a
macroscopically negative resection was sufficient for non-invasive
IPMN. Limitations of the study include the small sample size, a
lack of details on post-operative imaging and determination of
recurrence based solely on re-operation or biopsy. In a larger
study by Fujii et al.,15 103 patients operated on for non-invasive
IPMN were followed for evidence of recurrent disease. As in the
previous studies, pathological confirmation of IPMN or cancer on
re-operation or biopsy was needed to document recurrence.
Twenty-seven per cent of patients had a positive surgical margin at
initial resection ranging from adenoma to carcinoma in situ. At a
median follow-up of 41 months, 10% of patients were found to
have recurrent disease in the remnant gland. Of those who
recurred, none did so at the surgical margin and recurrence was
irrespective of the margin status at the time of initial operation.
From this, the authors concluded that the status of the final sur-
gical margin is not associated with recurrence after resection of
non-invasive IPMN.
Because the number of patients and incidence of recurrence in
studies of IPMN tends to be low, a meta-analysis was performed
specifically addressing the issue of margin positivity.16 Twelve
studies and 701 patients were included in the analysis with a
cumulative recurrence rate of 4.9%. A statistically different recur-
rence rate existed between those patients with (9.6%) and without
(3.7%) a positive surgical margin (P = 0.01). Based on these find-
ings, the authors concluded that a resection to a microscopically
negative margin was optimal in non-invasive IPMN. There was
significant heterogeneity in the length of follow-up and definition
of recurrence in the included studies and no mention of site of
recurrence within the remnant gland.
A study from our institution in 200717 looked at the incidence
of recurrent IPMN when PanIN or IPMN was present at the
Table 6 Multivariate predictors of recurrent disease
Odds ratio P-value
Location of cyst 0.01
Head Referent
Body 4.3
Tail 1.8
Degree of dysplasia 0.77
Adenoma Referent
Moderate 1.3
High grade 1.5
Distribution of dysplasia 0.79
Branch duct Referent
Main duct 0.8
Mixed type 1.3
PanIN in gland 1.3 0.50
Any dysplasia at margin 2.9 0.02
(a)
P = 0.001
0 months 12 months 24 months 36 months 48 months 60 months
0 months 12 months 24 months 36 months 48 months 60 months
P = 0.55
(b)
Disease-free survival
Figure 3 Overall and recurrence-free survival by margin status.
(a) Recurrence-free survival by margin status. (b) Overall survival
by margin status
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surgical margin. Of 72 patients with non-invasive IPMN, six
patients recurred which was defined as development of metastatic
pancreatic adenocarcinoma (3 patients) or re-operation for a new
pancreatic cyst (3 patients). Of the six recurrences, four had posi-
tive surgical margins for IPMN and the incidence of recurrence in
margin positive patients was 17%, compared with 2% in the
margin negative population (P = 0.02). One of the difficulties
identified in this paper was the ability to accurately identify IPMN
on a frozen section of the pancreatic margin. In this study, a frozen
section of the margin was performed in 27 patients, and the posi-
tive and negative predictive values of ‘IPMN at the margin’ on
frozen section were 50% and 74%, respectively. These findings
suggest that if we had extended the resection for a positive margin,
then in half of the cases this would not have been necessary as the
final pathology revealed no disease.
Missing from many of these prior series is inclusion of patients
with recurrence visualized only on cross-sectional imaging as well
as the significance of PanIN at the final surgical margin. In the
present study, 20% of patients had surgical margins positive for
IPMN with a majority exhibiting low- or moderate-grade dyspla-
sia. PanIN was present at the margin in nearly 28% of patients
with only 4 patients having high grade dysplasia (PanIN 3)
present. In all, the overall margin positivity rate (IPMN and
PanIN) was 45% which was similar to previous reports.17 Predic-
tors of margin positivity included moderate- or high-grade dys-
plasia in the index lesion and PanIN present in the extra-cystic
pancreatic duct. The latter suggests a diffuse duct process in which
multiple or more widespread areas of epithelial irregularity exist,
making dysplasia at the ductal margin more probable.
This concept of a pancreatic duct ‘field defect’ is supported by
previous studies of pathological analysis of resected specimens
where multicentric ductal dysplasia was frequently encountered.25
Further evidence comes from clinical observations that pancreatic
adenocarcinoma can develop at sites distant from the index cyst in
patients after pancreatic resection for IPMN as well as those fol-
lowed radiographically for small cysts.17,26 In the present series,
location of the resected cyst was also associated with margin status
with body and tail lesions having a near four-fold increase in
margin positivity. One possible explanation for this was the 67%
incidence in positive margins in those undergoing a central pan-
createctomy for body lesions.
A frozen section was used sparingly in this study with 23% of
margins assessed intra-operatively. Of those, 39% were positive
with a vast majority showing evidence of low-grade dysplasia and
only four patients exhibiting moderate- or high-grade dysplasia.
Re-resection of the margin was performed in four patients with
pathological clearance achieved in only two of those. We again
have demonstrated the relatively poor accuracy of a frozen section
in identifying dysplasia at the margin after resection of IPMN.
At a median follow-up of 46 months, 21% of patients had
recurrent disease with a majority of these showing evidence of
new cysts presumed to be IPMN on imaging. Six patients under-
went re-operation which confirmed recurrent non-invasive IPMN
in five and three developed pancreas adenocarcinoma. Predictors
of recurrent disease included location of the index lesion in the
body or tail or dysplasia at the final surgical margin. The latter was
associated with a three-fold increased risk and seemed to be inde-
pendent of the degree of dysplasia at the margin. Of note, while
the degree of dysplasia of the resected IPMN was associated with
the rate of margin positivity, it did not seem to be associated with
recurrence rates (Fig. 2). To further clarify the association of
margin status on recurrence, all cross-sectional imaging and
operative reports were re-reviewed to determine whether disease
developed at the transection margin or elsewhere in the gland. Of
the 40 patients who recurred, 6 had new lesions develop adjacent
to the prior resection with only 3 having disease restricted to the
transection margin alone. The remainder recurred elsewhere in
the remnant gland.Of the 6 patients that had amargin recurrence,
half had a negative surgical margin at in their initial resection.
These findings suggest that although a positive margin is associ-
ated with recurrent disease, it is likely a marker of diffuse ductal
instability and not a local oncologic failure. The low incidence of
disease recurrence at the actual site of resection suggests no need
to achieve a microscopically negative margin in non-invasive
IPMN making an intra-operative frozen section and re-resection
unnecessary. This is further supported by the observation that,
although margin positive patients had a worse recurrence-free
survival, there was no difference in overall-survival highlighting
the relative benign nature of non-invasive IPMN (Fig. 3).
Current guidelines recommend stratification of surveillance of
the remnant pancreas based on findings from the initial opera-
tion.6 High-risk patients are assessed every 3–9 months with
cross-sectional imaging whereas low-risk patients may be
screened annually. Because a margin negative resection is associ-
ated with a low rate of recurrence, perhaps the interval between
screening may be lengthened in this population, although long-
term follow-up supporting this conclusion is lacking. In conclu-
sion, these data suggest that when dysplasia is present at multiple
locations within the pancreas such as the surgical margin and/or
extra-cystic duct, patients are at increased risk of developing
recurrent IPMN supporting the concept of a ‘field defect’.
Although these patients may require closer follow-up with cross-
sectional imaging to identify recurrent lesions, the overall risk of
progression to invasive disease is low, and therefore an extended
resection or reoperation does not seem justified at this time.
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